ReviewJournal of lipid and atherosclerosis2021
Immunologic Aspects of Dyslipidemia: a Critical Regulator of Adaptive Immunity and Immune Disorders.
Review in Journal of lipid and atherosclerosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Review
- The importance of ovary-immune interactions in the context of age and disease.Frontiers in neuroendocrinology · 2026Review
- Integrative analysis of the gut microbiota, bile acid pathways, and immune dysregulation in dyslipidemia models.iScience · 2025Article
- Prevalence and Patterns of Dyslipidemia Among Patients With Rheumatoid Arthritis: A Retrospective Cohort Study.Cureus · 2025Article
- Common Pathophysiological Mechanisms Connecting Dyslipidemia and Hyperuricemia: a Narrative Review.Maedica · 2025Review
- T Cell Involvement in Neuroinflammation After Traumatic Brain Injury: Implications for Therapeutic Intervention.CNS neuroscience & therapeutics · 2025Review
- Symptomatic Trends and Time to Recovery for Long COVID Patients Infected During the Omicron Phase.Journal of clinical medicine · 2025Article
- The Role of Type I Interferons in Tuberculosis and in Tuberculosis-Risk-Associated Comorbidities.Infectious disease reports · 2025Review
- The Junction of Allergic Inflammation and Atherosclerosis: Pathways and Clinical Implications-A Review.Life (Basel, Switzerland) · 2025Review
- Correlation between dyslipidaemia and gastric cancer: pathogenesis to prevention and treatment strategies.Lipids in health and disease · 2025Review
- A machine learning-based risk prediction model for diabetic oral ulceration.BMC oral health · 2025Article
- Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses.Biomolecules · 2025Review
- ENaC gene variants and their involvement in Covid‑19 severity.Biomedical reports · 2024Article
- Article
- Article
- Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review.Biology · 2024Article
- Increasing HbA1c is associated with reduced CD8Cellular and molecular life sciences : CMLS · 2024Article
- Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation.Cells · 2023Review
- Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers.Vaccines · 2023Article
- Analysis of Hepatic Lipid Metabolism and Immune Function During the Development of Collagen-Induced Arthritis.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia is a major cause of cardiovascular diseases which represent a leading cause of death in humans. Diverse immune cells are known to be involved in the pathogenesis of cardiovascular diseases such as atherosclerosis. Conversely, dyslipidemia is known to be tightly associated with immune disorders in humans, as evidenced by a higher incidence of atherosclerosis in patients with autoimmune diseases including psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. Given that the dyslipidemia-related autoimmune diseases are caused by autoreactive T cells and B cells, dyslipidemia seems to directly or indirectly regulate the adaptive immunity. Indeed, accumulating evidence has unveiled that proatherogenic factors can impact the differentiation and function of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.